Four candidates for the COVID-19 vaccine are in various stages of human trials, while one, developed by Genique Life Sciences, is in an advanced preclinical phase, Union Science and Technology Minister Jitendra Singh said on Tuesday.
In a written response to a question in Rajya Sabha, Singh said the candidate for the vaccine was based on DNA from Cadila Healthcare Ltd in the third phase of a clinical trial. He also submitted temporary data for approval for emergency use.
The candidate for the vaccine of the company Biological E Ltd is also in the third phase of the clinical trial.
The candidate for the adeno intranasal vaccine Adeno for Bharat Biotech International Ltd is in the third phase of the clinical trial, while the candidate for the mRNA vaccine Gennova Biopharmaceuticals Ltd is in the first phase of the clinical trial.
Candidate for vaccine Genique Life Sciences Pvt Ltd based in Gurgaon is in an advanced preclinical phase, Singh said.
Currently, three vaccines are used in India – the Covishield Serum Institute of India, Bharat Biotech Covaxin and the Russian Sputnik V — vaccine.
Singh said that the COVID Suraksha mission – India’s COVID-19 vaccine development mission was announced as part of the third “Atmanirbhar Bharat 3.0” incentive package to promote research and development of Indian COVID-19 vaccines.
“The mission supports the development of four vaccine candidates in the clinical development phase and one vaccine candidate in the preclinical development phase.
“The clinical development of vaccine candidates is taking place at clinical trial sites located in Pan-India,” he added.